- Home
- GH
as of 12-02-2025 3:57pm EST
$103.60
$1.63
-1.54%
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Chart Type:
Time Range:
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 4.9B | IPO Year: | 2018 |
| Target Price: | $79.19 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $29.91 - $112.42 | Next Earning Date: | 10-29-2025 |
| Revenue: | $902,569,000 | Revenue Growth: | 30.38% |
| Revenue Growth (this year): | 34.72% | Revenue Growth (next year): | 26.46% |
AI-Powered GH Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 73.47%
73.47%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Guardant Health Inc. (GH)
Tariq Musa
Sell
Director
GH Nov 19, 2025
Avg Cost/Share
$96.25
Shares
116
Total Value
$11,165.00
Owned After
7,859
SEC Form 4
Saia John G.
Sell
Chief Legal Officer
GH Nov 7, 2025
Avg Cost/Share
$96.25
Shares
8,996
Total Value
$865,865.00
Owned After
43,172
SEC Form 4
Hidalgo Medina Manuel
Sell
Director
GH Nov 7, 2025
Avg Cost/Share
$95.20
Shares
1,500
Total Value
$142,780.15
Owned After
815
Tariq Musa
Sell
Director
GH Oct 17, 2025
Avg Cost/Share
$66.95
Shares
116
Total Value
$7,766.20
Owned After
7,859
SEC Form 4
POTTER MYRTLE S
Sell
Director
GH Oct 17, 2025
Avg Cost/Share
$66.95
Shares
26
Total Value
$1,740.70
Owned After
18,324
SEC Form 4
Tariq Musa
Sell
Director
GH Sep 17, 2025
Avg Cost/Share
$55.63
Shares
116
Total Value
$6,453.08
Owned After
7,859
SEC Form 4
POTTER MYRTLE S
Sell
Director
GH Sep 17, 2025
Avg Cost/Share
$55.63
Shares
26
Total Value
$1,446.38
Owned After
18,324
SEC Form 4
Hidalgo Medina Manuel
Sell
Director
GH Sep 12, 2025
Avg Cost/Share
$54.16
Shares
2,165
Total Value
$117,250.77
Owned After
815
SEC Form 4
Eltoukhy Helmy
Sell
Co-Chief Executive Officer
GH Sep 9, 2025
Avg Cost/Share
$59.69
Shares
300,000
Total Value
$17,835,995.20
Owned After
2,123,499
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Tariq Musa | GH | Director | Nov 19, 2025 | Sell | $96.25 | 116 | $11,165.00 | 7,859 | |
| Saia John G. | GH | Chief Legal Officer | Nov 7, 2025 | Sell | $96.25 | 8,996 | $865,865.00 | 43,172 | |
| Hidalgo Medina Manuel | GH | Director | Nov 7, 2025 | Sell | $95.20 | 1,500 | $142,780.15 | 815 | |
| Tariq Musa | GH | Director | Oct 17, 2025 | Sell | $66.95 | 116 | $7,766.20 | 7,859 | |
| POTTER MYRTLE S | GH | Director | Oct 17, 2025 | Sell | $66.95 | 26 | $1,740.70 | 18,324 | |
| Tariq Musa | GH | Director | Sep 17, 2025 | Sell | $55.63 | 116 | $6,453.08 | 7,859 | |
| POTTER MYRTLE S | GH | Director | Sep 17, 2025 | Sell | $55.63 | 26 | $1,446.38 | 18,324 | |
| Hidalgo Medina Manuel | GH | Director | Sep 12, 2025 | Sell | $54.16 | 2,165 | $117,250.77 | 815 | |
| Eltoukhy Helmy | GH | Co-Chief Executive Officer | Sep 9, 2025 | Sell | $59.69 | 300,000 | $17,835,995.20 | 2,123,499 |
Latest Guardant Health Inc. News
GH Breaking Stock News: Dive into GH Ticker-Specific Updates for Smart Investing
Simply Wall St.
Guardant Health (GH): Valuation in Focus After Obamacare Subsidy Extension Proposal Spurs Stock Surge
📈
AI Sentiment
Highly Positive
8/10
Compare GH vs Leading Stocks
See how GH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GH Guardant Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.